Annexon, Inc. (ANNX) News
Track canonical SquawkNews coverage tagged to ANNX, Annexon, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ANNX Reports Q2 2026 Financial Results
ANNX reports second quarter 2026 financial results and business updates
EARNINGS | Aug 12, 2026, 10:05 AM UTC
M
ANNX Expands Vonaprument Phase 3 Program
ANNX expands Vonaprument Phase 3 program in geographic atrophy
EQUITY | Aug 12, 2026, 10:00 AM UTC
H
Annexon Reports Positive Clinical Responses
Annexon's GBS FORWARD study shows positive responses
EQUITY | Aug 06, 2026, 12:00 PM UTC
H
Annexon secures $200M credit facility
Annexon gets $200M credit facility
EQUITY | Jul 30, 2026, 08:02 PM UTC
L
ANNX Initiated Underperform and $3 PT @ Citizens
ANNX Initiated Underperform and $3 PT @ Citizens
EQUITY | Jul 21, 2026, 12:04 PM UTC
L
ANNX PT raised from $11 to $25, maintains Buy @ Needham
ANNX PT raised from $11 to $25, maintains Buy @ Needham
EQUITY | Jul 15, 2026, 12:33 PM UTC
L
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Let
ANNX Annexon Inc. - Annexon to Present Phase 2 Archer Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
EQUITY | Jul 14, 2026, 08:14 PM UTC